The approval of a controversial new drug for Alzheimer's disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging.
from Google Alert - health https://ift.tt/3CeHIlx
via IFTTT
0 comments:
Post a Comment